1. Home
  2. HTGC vs LQDA Comparison

HTGC vs LQDA Comparison

Compare HTGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$16.60

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$39.04

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTGC
LQDA
Founded
2003
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
HTGC
LQDA
Price
$16.60
$39.04
Analyst Decision
Buy
Strong Buy
Analyst Count
7
10
Target Price
$21.00
$38.60
AVG Volume (30 Days)
1.9M
1.9M
Earning Date
02-12-2026
03-18-2026
Dividend Yield
11.20%
N/A
EPS Growth
N/A
N/A
EPS
1.75
N/A
Revenue
$516,847,000.00
$69,216,000.00
Revenue This Year
$10.13
$993.31
Revenue Next Year
$9.62
$219.14
P/E Ratio
$9.58
N/A
Revenue Growth
4.54
343.41
52 Week Low
$15.65
$11.26
52 Week High
$22.04
$46.67

Technical Indicators

Market Signals
Indicator
HTGC
LQDA
Relative Strength Index (RSI) 30.20 47.22
Support Level $16.22 $38.88
Resistance Level $17.00 $46.67
Average True Range (ATR) 0.38 2.44
MACD -0.16 -0.72
Stochastic Oscillator 15.12 2.70

Price Performance

Historical Comparison
HTGC
LQDA

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: